Syndax to Announce Fourth Quarter and Year-end 2022 Financial Results and Host Conference Call and Webcast on February 28, 2023

Rhea-AI Summary

Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) announced that it will report its fourth quarter and year-end 2022 financial results on February 28, 2023, after the U.S. market close. The management will conduct a conference call and live audio webcast at 4:30 p.m. ET the same day to discuss these results and provide a business update. Investors can access the webcast through the company's website and a replay will be available 24 hours after the call for 90 days. Syndax is focused on developing cancer therapies, with its pipeline including revumenib and axatilimab, which are in pivotal trials.

Positive

• Upcoming earnings release on February 28, 2023 highlights potential positive financial developments.
• Management hosting a conference call suggests transparency and engagement with investors.

Negative

• None.

WALTHAM, Mass., Feb. 21, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its fourth quarter and year-end 2022 financial results and provide a business update on Tuesday, February 28, after the close of the U.S. financial markets.

In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Tuesday, February 28, 2023 to discuss the Company's financial results and provide a business update.

The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website. Alternatively, the conference call may be accessed through the following:

Conference ID: SNDXQ422
Domestic Dial-in Number: 800-245-3047
International Dial-in Number: 203-518-9765
Live webcast: https://www.veracast.com/webcasts/OpenEx/General/SNDXQ4.cfm

For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company's website at www.syndax.com approximately 24 hours after the conference call and will be available for 90 days following the call.

About Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective inhibitor of the Menin–KMT2A binding interaction, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, both currently in pivotal trials. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn. 

Syndax Contact

Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com 
Tel 781.684.9827

SNDX-G

View original content:https://www.prnewswire.com/news-releases/syndax-to-announce-fourth-quarter-and-year-end-2022-financial-results-and-host-conference-call-and-webcast-on-february-28-2023-301751211.html

SOURCE Syndax Pharmaceuticals, Inc.

FAQ

When will Syndax Pharmaceuticals report its financial results for 2022?

Syndax Pharmaceuticals will report its fourth quarter and year-end 2022 financial results on February 28, 2023.

What time is the conference call for Syndax Pharmaceuticals' earnings release?

The conference call will take place at 4:30 p.m. ET on February 28, 2023.

How can I access the earnings call for Syndax Pharmaceuticals?

The earnings call will be accessible via the company's website and can also be dialed in using the provided numbers.

What therapies are in Syndax Pharmaceuticals' pipeline?

Syndax's pipeline includes revumenib and axatilimab, both of which are currently in pivotal trials.